Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Erectile dysfunction after sickle cell disease-associated recurrent ischemic priapism: profile and risk factors
source: The Journal of Sexual Medicine
year: 2015
authors: Anele UA, Burnett AL
summary/abstract:INTRODUCTION:
Risk factors associated with erectile dysfunction (ED) that results from recurrent ischemic priapism (RIP) in sickle cell disease (SCD) are incompletely defined.
AIM:
This study aims to determine and compare ED risk factors associated with SCD and non-SCD-related “minor” RIP, defined as having ≥2 episodes of ischemic priapism within the past 6 months, with the majority (>75%) of episodes lasting METHODS:
We performed a retrospective study of RIP in SCD and non-SCD patients presenting from June 2004 to March 2014 using the International Index of Erectile Function (IIEF), IIEF-5, and priapism-specific questionnaires.
MAIN OUTCOME MEASURES:
Prevalence rates and risk factor correlations for ED associated with RIP.
RESULTS:
The study was comprised of 59 patients (40 SCD [mean age 28.2 ± 8.9 years] and 19 non-SCD [15 idiopathic and four drug-related etiologies] [mean age 32.6 ± 11.7 years]). Nineteen of 40 (47.5%) SCD patients vs. four of 19 (21.1%) non-SCD patients (39% overall) had ED (IIEF CONCLUSIONS:
ED is associated with RIP, occurring in nearly 40% of affected individuals overall. SCD patients are more likely to experience ED in the setting of “very minor” RIP episodes and are five times more likely to develop ED compared with non-SCD patients.
DOI: 10.1111/jsm.12816
read more full text
Related Content
-
Sickle Cell Patients are Innocent Victims of the Opioid Epidemic: Samir K. Ballas, MDhttps://www.youtube.com/watch?v=BOhY_gJo...
-
Disability evaluation under social security (hematological disorders-adult)A. What hematological disorders do we ev...
-
Sickle Cell Disease: Pain ManagementPain is a long-lasting problem for peopl...
-
Sickle Cell and Young Stroke SurvivorsSickle Cell & Young Stroke Survivors...
-
Orphan Drug Designation Granted for CSL Behring’s Investigational Plasma-Derived Hemopexin Therapy for Sickle ...Global biotherapeutics leader CSL Behrin...
-
First systemic evidence for safety of tPA in stroke patients with sickle cell diseaseIn the largest report on acute stroke in...
-
When Cracking Down On Opioids Means Tougher Access For Sickle Cell PatientsMany people with sickle cell disease wil...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.